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Anti-Neutrophil Cytoplasmic Antibodies (ANCA)-associated vasculitides (AAV) are characterized by small
vessel injury and in some cases granulomatous lesions and glomerular inﬂammation. The pathogenic
bases of these clinical phenotypes are incompletely understood, but evidence from patients with AAV
and other inﬂammatory diseases suggest a role for monocyte/macrophages in the perpetuation of tissue
injury. Macrophage colony stimulating factor (M-CSF) is a promoter of monocyte recruitment and
macrophage proliferation, involved in mesangial cell proliferation and experimental nephritis develop-
ment. Serum concentrations of M-CSF mark and herald the onset of lupus nephritis. Plasma samples from
29 patients with AAV (18 granulomatosis with polyangiitis, GPA, 6 eosinophilic granulomatosis with
polyangiitis, EGPA, and 5 microscopic polyangiitis, MPA) and from 10 healthy controls were collected
together with clinical data. Patients with AAV had higher levels of M-CSF when compared to controls. M-
CSF levels correlated positively with the BVAS, serum C-reactive protein and erythrocyte sedimentation
rate, while haemoglobin correlated inversely with M-CSF. Patients with active renal disease had sig-
niﬁcantly higher levels of M-CSF when compared to the other subgroups. M-CSF levels did not differ
between ANCA subserotypes and were not associated with the involvement of other organs. In con-
clusion, M-CSF is higher in patients with AAV and active nephritis and could contribute to the patho-
genesis of these diseases. In addition, M-CSF could behave as a useful marker of renal involvement
in AAV.
& 2015 Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Renal involvement represents the most severe manifestation of
ANCA-associated vasculitides (AAV) and the leading cause of
chronic damage accrual [1], despite the lack of speciﬁc biomarkers
to guide the Clinician’s diagnostic and therapeutic decisions [2].
Macrophage colony stimulating factor (M-CSF) is a promoter of
monocyte recruitment and macrophage proliferation [3,4]. Circu-
lating levels of M-CSF are increased in patients with chronic renal
failure, possibly as a consequence of immune dysregulation during
uraemia, since M-CSF metabolism is independent of the renal
function [5]. Furthermore, M-CSF is involved in mesangial cell
proliferation and acts in synergy with LPS to prompt macrophage
recruitment from the bloodstream in experimental nephritis [3,4].
Previous studies also documented increased levels of M-CSF ins article under the CC BY-NC-ND li
ine and Immunology, IRCCS
o, Italy.
. Ramirez).sera and renal biopsies of patients with proliferative glomer-
ulonephritis (GN) and in particular lupus nephritis (LN) [6,7]. In
addition, recent works showed that serum concentrations of M-
CSF marked and heralded the onset of LN in two large lupus
cohorts [6]. By contrast, no speciﬁc evidence is available to date
about a role of M-CSF in AAV, despite pathogenic similarities
between AAV and other forms of kidney inﬂammation, such as LN
[8]. In this study, we thus aimed at evaluating a role of M-CSF as a
biomarker of disease activity and organ involvement in AAV.2. Methods
Upon informed consent, plasma samples from 29 patients with
AAV (18 granulomatosis with polyangiitis, GPA, 6 eosinophilic
granulomatosis with polyangiitis, EGPA, and 5 microscopic poly-
angiitis, MPA) and from 10 healthy controls were collected toge-
ther with data regarding clinical history, disease activity (as esti-
mated by the Birmingham Vasculitis Activity Score, BVAS) at the
time of venepuncture, routine laboratory parameters and markerscense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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urinary sediment. According to the clinical phenotype, AAV
patients were divided in patients with active renal disease,
patients with active disease without renal involvement, patients in
remission with past history of renal involvement, patients in
remission with no history of renal involvement. M-CSF plasma
concentration was assessed by using a commercial assay (Human
M-CSF Quantikines ELISA Kit, R&D Systems, Minneapolis, MN). M-
CSF levels were also standardized for GFR by deﬁning a speciﬁc
variable resulting from the product M-CSF*ln(GFR). Differences in
normally distributed continuous variables (creatinine; glomerular
ﬁltration rate, GFR) among groups were measured by employing
the ANOVA with Bonferroni’s correction, whereas non-normally
distributed continuous variables (M-CSF) were analysed by using
the Mann–Whitney U-test or the Kruskall–Wallis test for multiple
comparisons. Correlations between continuous variables were
assessed by using the Spearman’s test. Data are expressed as
median (interquartile range), unless speciﬁcally indicated.3. Results
The clinical and serological phenotypes of patients with AAV
were equally distributed among disease groups (Table 1).
Patients with AAV had higher levels of M-CSF when compared
to controls (Fig. 1). The levels of M-CSF correlated positively with
erythrocyte sedimentation rate (ρ¼0.521; p¼0.022) and serum C-
reactive protein (ρ¼0.764; po0.001) and negatively with hae-
moglobin (ρ¼0.552; p¼0.012). Furthermore, M-CSF levels cor-
related positively with the BVAS (ρ¼0.472; p¼0.010).
Patients with active renal disease had signiﬁcantly higher levels
of M-CSF when compared to patients with active disease and no
kidney involvement, with patients in remission with or without a
history of renal involvement and with healthy controls (p¼0.014;
p¼0.019; p¼0.002; po0.001 respectively; Fig. 1). Patients with
renal involvement and in particular those with active renal disease
had also higher creatinine levels and lower GFR (po0.05 towards
patients with active disease without renal involvement and
patients in remission without history of renal involvement), as
expected (Table 1). However, when M-CSF levels were standar-
dized for GFR, the differences among groups were not signiﬁcantly
affected (p¼0.001 between AAV patients and controls; p¼0.064,
p¼0.031, p¼0.007; po0.001 when comparing AAV patients with
active renal disease and patients with active disease without renal
involvement, patients in remission with a history of renal invol-
vement, patients in remission without a history of renal involve-
ment and healthy controls respectively). Patients with active
urinary sediment, signiﬁcant 24 h proteinuria and typical ﬁndingsTable 1
Clinical characteristics according to disease activity and renal involvement.
Active renal disease Active disease without r
involvement
Anti-PR3þ 6 1
Anti-MPOþ 3 3
GPA (N) 6 1
EGPA (N) 1 2
MPA (N) 2 1
Mean7SEM serum creatinine (mg/dl) 2.4070.64 0.8370.06
Mean7SEM glomerular ﬁltration rate
(ml/min)
38.5577.11n 92.7879.85n
n po0.05.at renal biopsy had also higher M-CSF levels although these
ﬁndings did not reach statistical signiﬁcance (Table 2).
M-CSF levels did not discriminate AAV serotype (anti-PR3/MPO
positive vasculitis) or phenotype (GPA, EGPA, MPA; Table 2), were
similar between genders and did not identify any other type of
organ involvement. In particular, circulating M-CSF in patients
with vasculitic lung involvement were comparable to those of
patients with nodular lesions only (Table 2).
Patients receiving prednisone alone at time of sample collection
(all in the induction phase while waiting to start an immune sup-
pressant) had signiﬁcantly higher M-CSF than those taking pre-
dnisone in combination with immune suppressants (p¼0.033). By
contrast, M-CSF levels did not correlate with prednisone dose at
venepuncture and were not signiﬁcantly different among patients
taking different immunosuppressive agents either for induction and
maintenance of remission. Although the study was not designed for
prospective evaluation, we also recorded data about disease activity
at 6 months from venepuncture: patients with persistent non-
remission or disease ﬂare had slightly higher M-CSF levels,
although the datum did not reach statistical signiﬁcance (Table 3).4. Discussion
In this brief report, we ﬁrst describe the presence of higher M-CSF
levels in patients with AAV. M-CSF correlated with clinical and bio-
chemical markers of systemic inﬂammation and showed a trend
towards a higher expression in patients who eventually experienced a
disease ﬂare or who did not reach remission 6 months after sample
collection. The highest M-CSF levels were detected in patients with
active renal disease. Consistently, we also observed a trend towards a
higher M-CSF expression in patients with active urinary sediment,
signiﬁcant 24 h proteinuria and typical histological ﬁndings at renal
biopsy. Unfortunately, these data did not reach statistical signiﬁcance,
possibly because of the limited sample size. Patients with active renal
disease had also signs of impaired renal function, as documented by
lower GFR levels. When M-CSF levels were standardized for GFR only
minimal differences were observed, which possibly reﬂect the com-
mon inﬂuence of renal inﬂammation on both variables [5]. Previous
reports have in fact repeatedly described a general rise in circulating
M-CSF in patients with renal disease [5] and a signiﬁcantly higher local
and systemic expression of M-CSF in patients with proliferative GN,
class III and IV LN in particular [6,7]. In this latter context, extensive
studies, both in vitro and in vivo, dissected the precise role of M-CSF
and its isoforms in prompting the recruitment of circulating mono-
cytes into the glomerulus to cause GN [9].
Unfortunately, less is known about the pathogenic role of M-
CSF in AAV. However, evidence from AAV disease models suggest
that: (a) M-CSF plays a non-redundant role in experimentalenal History of renal
involvement
No history of renal
involvement
Total AAV
8 3 18
1 4 11
8 3 18
0 3 6
1 1 5
1.2170.24 0.8870.11 1.4770.25
72.78711.32 90.7579.63n 68.4976.34
Fig. 1. Plasma M-CSF in AAV and healthy controls. M-CSF levels discriminate between patients with AAV and healthy controls. M-CSF levels are higher in patients with
active renal disease. SEM: standard error of mean. npo0.001, signiﬁcantly different from controls; §: p¼0.014, p¼0.019, p¼0.002 and po0.001, signiﬁcantly different from
patients with active disease without renal involvement, from patients in remission with a history of renal involvement, from patients in remission without a history of renal
involvement and from healthy controls respectively.
Table 2
M-CSF levels according to clinical features.
Groups N M-CSF (pg/ml) p
Vasculitis serotype
Anti-PR3 – vasculitis 18 289.08 (197.36–622.47) NS
Anti-MPO – vasculitis 11 327.13 (159.49–432.75)
Vasculitis phenotype
GPA 18 289.08 (197.36–622.47) NS
EGPA 6 159.49 (107.71–325.95)
MPA 5 385.09 (327.13–480,41)
Histological ﬁndingsa
Diagnostic renal biopsy 8 460.61 (313.32–868.86) NS
Diagnostic biopsy in non-renal tissues 6 205.30 (121.00–284.99)
Non-diagnostic biopsy 7 231.75 (204.77–607.15)
Urinary sediment in patients with renal involvement
Active 3 1258.35 (251.77–581.72) NS
Non active 11 386.03 (792.74–1429.48)
Presence of proteinuria in patients with renal involvement
Proteinuria present 7 480.41 (383.97–970.69) NS
Proteinuria absent 7 271.90 (226.42–644.33)
Pulmonary phenotypes
Alveolar haemorrhage 3 231.65 (161.52–308.37) NS
Nodular lesions without alveolitis 11 386.03 (247.84–909.62)
a In eight cases no biopsy was performed.
Table 3
M-CSF levels according to therapeutic regimens and outcomes.
Groups N M-CSF (pg/ml) p
Prednisone at venepuncture
Steroid therapy 21 297.69 (189.42–440.81) NS
Steroid free 8 350.42 (166.76–638.16)
Therapeutic regimen at venepuncture
Prednisoneþ Immune suppressants 22 251.77 (157.57–370.60) 0.033
Prednisone only 4 869.38 (418.25–1343.92)
Rituximab 3 150.80 (121.09–211.35) NS
Methotrexate 9 221.19 (136.27–306.26)
Azathioprine 8 279.39 (187.74–399.73)
Others (cyclophosphamide,
mycophenolate)
2 534.06 (459.57–608.54)
Any therapy 26 284.80 (179.10–427.12) NS
No therapy 3 902.63 (638.16–1232.80)
Outcome at 6 monthsa
Remission 20 251.82 (171.12–460.28) NS
No remission/ﬂare 8 373.54 (278.57–545.07)
a One patient lost at follow up.
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ment (possibly through M-CSF released from tubular epithelial
cells) from the bloodstream is a shared pathogenic event in LN and
AAV [8,9]. We thus propose that M-CSF could play a pathogenic
and clinical role as a marker in AAV with nephritic manifestations.
We acknowledge the limitations of our study, in particular the
small sample size, which warrants the validations of our data in
another larger cohort. We are also aware that a prospective and
multiparametric (i.e. including a pool of candidate cytokines in
parallel) would better prove the speciﬁcity of M-CSF as a marker of
renal inﬂammation in AAV, conﬁrming and extending our
current data.5. Conclusions
To the best of our knowledge, this is the ﬁrst study to explore
M-CSF expression in AAV. This cytokine plays a fundamental role
in macrophage recruitment at sites of renal inﬂammation, a crucial
event in the development of proliferative GN. Our data, in line
with those reported in similar pathological conditions, suggest a
selective expression of M-CSF in AAV with active nephritis and a
potential role of M-CSF as a universal marker of proliferative GN.
Larger studies are warranted to conﬁrm this hypothesis and fur-
ther investigate the role of M-CSF in the pathogenesis of this group
of diseases.Conﬂict of interest statement
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